Literature DB >> 31378558

Drug-resistant epilepsy: From multiple hypotheses to an integral explanation using preclinical resources.

Daniel Pérez-Pérez1, Christian L Frías-Soria2, Luisa Rocha3.   

Abstract

Drug-resistant epilepsy affects approximately one-third of the patients with epilepsy. The pharmacoresistant condition in epilepsy is mainly explained by six hypotheses. In addition, several experimental models have been used to understand the mechanisms involved in pharmacoresistant epilepsy and to identify novel therapies to control this condition. However, the global prevalence of this disease persists without changes. Several factors can explain this situation. First of all, the pharmacoresistant epilepsy is explained by different and independent hypotheses. Each hypothesis indicates specific mechanisms to explain the drug-resistant condition in epilepsy. However, there are different findings suggesting common mechanisms between the different hypotheses. Other important situation is that the experimental models designed for the screening of drugs with potential anticonvulsant effect do not consider factors such as age, gender, type of epilepsy, and comorbid disorders. The present review focuses on indicating the limitations for each hypothesis and the relationships among them. The relevance to consider central and peripheral phenomena associated with the drug-resistant condition in different types of epilepsy is also indicated. The necessity to establish a global hypothesis that integrates all the phenomena associated with the pharmacoresistant epilepsy is proposed. This article is part of the Special Issue "NEWroscience 2018".
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Drug resistance; Experimental models; Hypotheses

Year:  2019        PMID: 31378558     DOI: 10.1016/j.yebeh.2019.07.031

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  8 in total

Review 1.  Levetiracetam Mechanisms of Action: From Molecules to Systems.

Authors:  Itzel Jatziri Contreras-García; Noemí Cárdenas-Rodríguez; Antonio Romo-Mancillas; Cindy Bandala; Sergio R Zamudio; Saúl Gómez-Manzo; Beatriz Hernández-Ochoa; Julieta Griselda Mendoza-Torreblanca; Luz Adriana Pichardo-Macías
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-13

2.  Polygonogram and isobolographic analysis of interactions between various novel antiepileptic drugs in the 6-Hz corneal stimulation-induced seizure model in mice.

Authors:  Jarogniew J Luszczki; Anna Panasiuk; Mirosław Zagaja; Sławomir Karwan; Hubert Bojar; Zbigniew Plewa; Magdalena Florek-Łuszczki
Journal:  PLoS One       Date:  2020-06-01       Impact factor: 3.240

Review 3.  Transporter hypothesis in pharmacoresistant epilepsies. Is it at the central or peripheral level?

Authors:  Liliana Czornyj; Jerónimo Auzmendi; Alberto Lazarowski
Journal:  Epilepsia Open       Date:  2021-10-29

Review 4.  Introduction to the special issue "Redesigning the hypotheses for drug-resistant epilepsy".

Authors:  Luisa Rocha
Journal:  Epilepsia Open       Date:  2022-02-04

Review 5.  A complex systems view on the current hypotheses of epilepsy pharmacoresistance.

Authors:  Gabriel Servilha-Menezes; Norberto Garcia-Cairasco
Journal:  Epilepsia Open       Date:  2022-03-11

Review 6.  The gut microbiome in drug-resistant epilepsy.

Authors:  Simela Chatzikonstantinou; Georgia Gioula; Vasilios K Kimiskidis; Jack McKenna; Ioannis Mavroudis; Dimitrios Kazis
Journal:  Epilepsia Open       Date:  2021-01-13

7.  Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment.

Authors:  Claudia Taborda Gómez; Fabiana Lairion; Marisa Repetto; Miren Ettcheto; Amalia Merelli; Alberto Lazarowski; Jerónimo Auzmendi
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-05

8.  Seizure semiology in temporal lobe vs. temporal plus epilepsy using intracranial EEG monitoring.

Authors:  Abeer Khoja; Omnyah Albaradei; Ashwaq Alsulami; Mohamed Alkhaja; Mohammad Alsumaili; Ohood Khoja; Alya Khoja; Mashael Al-Khateeb
Journal:  Neurosciences (Riyadh)       Date:  2021-07       Impact factor: 0.906

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.